Review





Similar Products

94
ABclonal Biotechnology parp1
Parp1, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cleaved+parp1/%5BKO+Validated%5D+Cleaved+PARP+p25+Rabbit+mAb/10__1186_slash_s40001___026___05241___8-145-32-34
Average 94 stars, based on 1 article reviews
parp1 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

96
Proteintech cleaved parp1
PADI inhibition potentiates KRAS-targeted therapies and overcomes acquired resistance (A) ATP levels in MIA PaCa-2 cells treated as indicated for 36 h under normoxia or hypoxia (2% O 2 ). (B) Clonogenic assay in the indicated MIA PaCa-2 cells treated as indicated for 30 h and then grown in 60-mm plates for 7 days. Colonies were stained with methylene blue. (C) Immunoblot analysis of the indicated proteins in MIA PaCa-2 cells (parental or treated once or three times with LC-2) and BxPC3, after 24 h of the indicated treatment. We labeled ERK1/2 as pERK1/2 when phosphorylated at Thr202/Tyr204. (D) Immunoblot analysis of the indicated proteins in MIA PaCa-2 (biallelic KRAS G12C ) and BxPC-3 (wild-type KRAS) cell lines treated as indicated for 24 h. Arrows indicate band shifts of KRAS molecules covalently bound by adagrasib or sotorasib. (E) Synergy plot in MIA PaCa-2 cells after 48 h in the presence of the indicated concentrations of sotorasib, LC-2, and BBCl. ATP levels were used as readouts of cell viability and metabolic activity. (F) Immunoblot analysis of the indicated proteins in MIA PaCa-2 ( KRAS G12C/G12C ), PANC-1 ( KRAS wt/G12D ), and SW620 ( KRAS G12V ) cells treated for 48 h with the indicated KRAS(OFF) and KRAS(ON) inhibitors. Arrows indicate band shifts of KRAS molecules covalently bound by RMC-9805. (G) Immunoblot analysis of the indicated proteins in PANC-1 cells treated for 48 h with the indicated μM concentrations of BBCl and/or RMC-9805. (H) Clonogenic assay in PANC-1 cells treated as indicated for 30 h and then grown in 35-mm plates for 7 days. (I) Clonogenic assay in PANC-1 RMCx3 cells treated as indicated for 30 h and then grown in 35-mm plates for 7 days. (J and K) Quantification of tumor volumes (J) and weight (K) in the BxPC-3 FLAG-KRAS G12C xenograft model. Nude mice were subcutaneously injected with 2 × 10 6 cells. When tumors reached a mean volume of ∼100 mm 3 , mice were randomized into four groups and treated intraperitoneally (i.p.) twice per week as indicated in  D. After the indicated number of days, mice were sacrificed, and tumors were excised (K). Data are expressed as mean ± st.error, n = 6. Statistical analysis was performed using one-way ANOVA followed by Bonferroni post hoc test.  (L) Immunoblot analysis of the indicated proteins and global peptidyl-citrullination levels in tumors excised from the indicated mice, corresponding to the numerical identifiers shown in K. Cleaved caspase-3 and covalent KRAS engagement by sotorasib are indicated. In (A, B, H, I, J, and K) data are presented as mean ± SD. In (A, B, H, I, and K), Dunn’s multiple comparison test was used. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.
Cleaved Parp1, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cleaved+parp1/PARP1+Antibody/pmc13714175-26-0-3
Average 96 stars, based on 1 article reviews
cleaved parp1 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

94
ABclonal Biotechnology cleaved parp1
PADI inhibition potentiates KRAS-targeted therapies and overcomes acquired resistance (A) ATP levels in MIA PaCa-2 cells treated as indicated for 36 h under normoxia or hypoxia (2% O 2 ). (B) Clonogenic assay in the indicated MIA PaCa-2 cells treated as indicated for 30 h and then grown in 60-mm plates for 7 days. Colonies were stained with methylene blue. (C) Immunoblot analysis of the indicated proteins in MIA PaCa-2 cells (parental or treated once or three times with LC-2) and BxPC3, after 24 h of the indicated treatment. We labeled ERK1/2 as pERK1/2 when phosphorylated at Thr202/Tyr204. (D) Immunoblot analysis of the indicated proteins in MIA PaCa-2 (biallelic KRAS G12C ) and BxPC-3 (wild-type KRAS) cell lines treated as indicated for 24 h. Arrows indicate band shifts of KRAS molecules covalently bound by adagrasib or sotorasib. (E) Synergy plot in MIA PaCa-2 cells after 48 h in the presence of the indicated concentrations of sotorasib, LC-2, and BBCl. ATP levels were used as readouts of cell viability and metabolic activity. (F) Immunoblot analysis of the indicated proteins in MIA PaCa-2 ( KRAS G12C/G12C ), PANC-1 ( KRAS wt/G12D ), and SW620 ( KRAS G12V ) cells treated for 48 h with the indicated KRAS(OFF) and KRAS(ON) inhibitors. Arrows indicate band shifts of KRAS molecules covalently bound by RMC-9805. (G) Immunoblot analysis of the indicated proteins in PANC-1 cells treated for 48 h with the indicated μM concentrations of BBCl and/or RMC-9805. (H) Clonogenic assay in PANC-1 cells treated as indicated for 30 h and then grown in 35-mm plates for 7 days. (I) Clonogenic assay in PANC-1 RMCx3 cells treated as indicated for 30 h and then grown in 35-mm plates for 7 days. (J and K) Quantification of tumor volumes (J) and weight (K) in the BxPC-3 FLAG-KRAS G12C xenograft model. Nude mice were subcutaneously injected with 2 × 10 6 cells. When tumors reached a mean volume of ∼100 mm 3 , mice were randomized into four groups and treated intraperitoneally (i.p.) twice per week as indicated in  D. After the indicated number of days, mice were sacrificed, and tumors were excised (K). Data are expressed as mean ± st.error, n = 6. Statistical analysis was performed using one-way ANOVA followed by Bonferroni post hoc test.  (L) Immunoblot analysis of the indicated proteins and global peptidyl-citrullination levels in tumors excised from the indicated mice, corresponding to the numerical identifiers shown in K. Cleaved caspase-3 and covalent KRAS engagement by sotorasib are indicated. In (A, B, H, I, J, and K) data are presented as mean ± SD. In (A, B, H, I, and K), Dunn’s multiple comparison test was used. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.
Cleaved Parp1, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cleaved+parp1/%5BKO+Validated%5D+Cleaved+PARP+p25+Rabbit+mAb/10__1016_slash_j__cej__2026__180066-117-43-50
Average 94 stars, based on 1 article reviews
cleaved parp1 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

86
Servicebio Inc anti cleaved parp1 rabbit pab
PADI inhibition potentiates KRAS-targeted therapies and overcomes acquired resistance (A) ATP levels in MIA PaCa-2 cells treated as indicated for 36 h under normoxia or hypoxia (2% O 2 ). (B) Clonogenic assay in the indicated MIA PaCa-2 cells treated as indicated for 30 h and then grown in 60-mm plates for 7 days. Colonies were stained with methylene blue. (C) Immunoblot analysis of the indicated proteins in MIA PaCa-2 cells (parental or treated once or three times with LC-2) and BxPC3, after 24 h of the indicated treatment. We labeled ERK1/2 as pERK1/2 when phosphorylated at Thr202/Tyr204. (D) Immunoblot analysis of the indicated proteins in MIA PaCa-2 (biallelic KRAS G12C ) and BxPC-3 (wild-type KRAS) cell lines treated as indicated for 24 h. Arrows indicate band shifts of KRAS molecules covalently bound by adagrasib or sotorasib. (E) Synergy plot in MIA PaCa-2 cells after 48 h in the presence of the indicated concentrations of sotorasib, LC-2, and BBCl. ATP levels were used as readouts of cell viability and metabolic activity. (F) Immunoblot analysis of the indicated proteins in MIA PaCa-2 ( KRAS G12C/G12C ), PANC-1 ( KRAS wt/G12D ), and SW620 ( KRAS G12V ) cells treated for 48 h with the indicated KRAS(OFF) and KRAS(ON) inhibitors. Arrows indicate band shifts of KRAS molecules covalently bound by RMC-9805. (G) Immunoblot analysis of the indicated proteins in PANC-1 cells treated for 48 h with the indicated μM concentrations of BBCl and/or RMC-9805. (H) Clonogenic assay in PANC-1 cells treated as indicated for 30 h and then grown in 35-mm plates for 7 days. (I) Clonogenic assay in PANC-1 RMCx3 cells treated as indicated for 30 h and then grown in 35-mm plates for 7 days. (J and K) Quantification of tumor volumes (J) and weight (K) in the BxPC-3 FLAG-KRAS G12C xenograft model. Nude mice were subcutaneously injected with 2 × 10 6 cells. When tumors reached a mean volume of ∼100 mm 3 , mice were randomized into four groups and treated intraperitoneally (i.p.) twice per week as indicated in  D. After the indicated number of days, mice were sacrificed, and tumors were excised (K). Data are expressed as mean ± st.error, n = 6. Statistical analysis was performed using one-way ANOVA followed by Bonferroni post hoc test.  (L) Immunoblot analysis of the indicated proteins and global peptidyl-citrullination levels in tumors excised from the indicated mice, corresponding to the numerical identifiers shown in K. Cleaved caspase-3 and covalent KRAS engagement by sotorasib are indicated. In (A, B, H, I, J, and K) data are presented as mean ± SD. In (A, B, H, I, and K), Dunn’s multiple comparison test was used. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.
Anti Cleaved Parp1 Rabbit Pab, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cleaved+parp1/3+anti+caspase+cleaved+%E2%97%A6/pmc13130678-17-0-5
Average 86 stars, based on 1 article reviews
anti cleaved parp1 rabbit pab - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

86
Abmart Inc jo urn al pr e p roo f cleaved parp1 abmart
PADI inhibition potentiates KRAS-targeted therapies and overcomes acquired resistance (A) ATP levels in MIA PaCa-2 cells treated as indicated for 36 h under normoxia or hypoxia (2% O 2 ). (B) Clonogenic assay in the indicated MIA PaCa-2 cells treated as indicated for 30 h and then grown in 60-mm plates for 7 days. Colonies were stained with methylene blue. (C) Immunoblot analysis of the indicated proteins in MIA PaCa-2 cells (parental or treated once or three times with LC-2) and BxPC3, after 24 h of the indicated treatment. We labeled ERK1/2 as pERK1/2 when phosphorylated at Thr202/Tyr204. (D) Immunoblot analysis of the indicated proteins in MIA PaCa-2 (biallelic KRAS G12C ) and BxPC-3 (wild-type KRAS) cell lines treated as indicated for 24 h. Arrows indicate band shifts of KRAS molecules covalently bound by adagrasib or sotorasib. (E) Synergy plot in MIA PaCa-2 cells after 48 h in the presence of the indicated concentrations of sotorasib, LC-2, and BBCl. ATP levels were used as readouts of cell viability and metabolic activity. (F) Immunoblot analysis of the indicated proteins in MIA PaCa-2 ( KRAS G12C/G12C ), PANC-1 ( KRAS wt/G12D ), and SW620 ( KRAS G12V ) cells treated for 48 h with the indicated KRAS(OFF) and KRAS(ON) inhibitors. Arrows indicate band shifts of KRAS molecules covalently bound by RMC-9805. (G) Immunoblot analysis of the indicated proteins in PANC-1 cells treated for 48 h with the indicated μM concentrations of BBCl and/or RMC-9805. (H) Clonogenic assay in PANC-1 cells treated as indicated for 30 h and then grown in 35-mm plates for 7 days. (I) Clonogenic assay in PANC-1 RMCx3 cells treated as indicated for 30 h and then grown in 35-mm plates for 7 days. (J and K) Quantification of tumor volumes (J) and weight (K) in the BxPC-3 FLAG-KRAS G12C xenograft model. Nude mice were subcutaneously injected with 2 × 10 6 cells. When tumors reached a mean volume of ∼100 mm 3 , mice were randomized into four groups and treated intraperitoneally (i.p.) twice per week as indicated in  D. After the indicated number of days, mice were sacrificed, and tumors were excised (K). Data are expressed as mean ± st.error, n = 6. Statistical analysis was performed using one-way ANOVA followed by Bonferroni post hoc test.  (L) Immunoblot analysis of the indicated proteins and global peptidyl-citrullination levels in tumors excised from the indicated mice, corresponding to the numerical identifiers shown in K. Cleaved caspase-3 and covalent KRAS engagement by sotorasib are indicated. In (A, B, H, I, J, and K) data are presented as mean ± SD. In (A, B, H, I, and K), Dunn’s multiple comparison test was used. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.
Jo Urn Al Pr E P Roo F Cleaved Parp1 Abmart, supplied by Abmart Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cleaved+parp1/anti+parp/pm41936920-499-110-120
Average 86 stars, based on 1 article reviews
jo urn al pr e p roo f cleaved parp1 abmart - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

97
Cell Signaling Technology Inc parp1 antibody cell signaling technology
PADI inhibition potentiates KRAS-targeted therapies and overcomes acquired resistance (A) ATP levels in MIA PaCa-2 cells treated as indicated for 36 h under normoxia or hypoxia (2% O 2 ). (B) Clonogenic assay in the indicated MIA PaCa-2 cells treated as indicated for 30 h and then grown in 60-mm plates for 7 days. Colonies were stained with methylene blue. (C) Immunoblot analysis of the indicated proteins in MIA PaCa-2 cells (parental or treated once or three times with LC-2) and BxPC3, after 24 h of the indicated treatment. We labeled ERK1/2 as pERK1/2 when phosphorylated at Thr202/Tyr204. (D) Immunoblot analysis of the indicated proteins in MIA PaCa-2 (biallelic KRAS G12C ) and BxPC-3 (wild-type KRAS) cell lines treated as indicated for 24 h. Arrows indicate band shifts of KRAS molecules covalently bound by adagrasib or sotorasib. (E) Synergy plot in MIA PaCa-2 cells after 48 h in the presence of the indicated concentrations of sotorasib, LC-2, and BBCl. ATP levels were used as readouts of cell viability and metabolic activity. (F) Immunoblot analysis of the indicated proteins in MIA PaCa-2 ( KRAS G12C/G12C ), PANC-1 ( KRAS wt/G12D ), and SW620 ( KRAS G12V ) cells treated for 48 h with the indicated KRAS(OFF) and KRAS(ON) inhibitors. Arrows indicate band shifts of KRAS molecules covalently bound by RMC-9805. (G) Immunoblot analysis of the indicated proteins in PANC-1 cells treated for 48 h with the indicated μM concentrations of BBCl and/or RMC-9805. (H) Clonogenic assay in PANC-1 cells treated as indicated for 30 h and then grown in 35-mm plates for 7 days. (I) Clonogenic assay in PANC-1 RMCx3 cells treated as indicated for 30 h and then grown in 35-mm plates for 7 days. (J and K) Quantification of tumor volumes (J) and weight (K) in the BxPC-3 FLAG-KRAS G12C xenograft model. Nude mice were subcutaneously injected with 2 × 10 6 cells. When tumors reached a mean volume of ∼100 mm 3 , mice were randomized into four groups and treated intraperitoneally (i.p.) twice per week as indicated in  D. After the indicated number of days, mice were sacrificed, and tumors were excised (K). Data are expressed as mean ± st.error, n = 6. Statistical analysis was performed using one-way ANOVA followed by Bonferroni post hoc test.  (L) Immunoblot analysis of the indicated proteins and global peptidyl-citrullination levels in tumors excised from the indicated mice, corresponding to the numerical identifiers shown in K. Cleaved caspase-3 and covalent KRAS engagement by sotorasib are indicated. In (A, B, H, I, J, and K) data are presented as mean ± SD. In (A, B, H, I, and K), Dunn’s multiple comparison test was used. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.
Parp1 Antibody Cell Signaling Technology, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cleaved+parp1/Cleaved+PARP+(Asp214)+XP+Rabbit+mAb/pm41886456-322-48-50
Average 97 stars, based on 1 article reviews
parp1 antibody cell signaling technology - by Bioz Stars, 2026-11
97/100 stars
  Buy from Supplier

99
Cell Signaling Technology Inc cleaved parp1
PADI inhibition potentiates KRAS-targeted therapies and overcomes acquired resistance (A) ATP levels in MIA PaCa-2 cells treated as indicated for 36 h under normoxia or hypoxia (2% O 2 ). (B) Clonogenic assay in the indicated MIA PaCa-2 cells treated as indicated for 30 h and then grown in 60-mm plates for 7 days. Colonies were stained with methylene blue. (C) Immunoblot analysis of the indicated proteins in MIA PaCa-2 cells (parental or treated once or three times with LC-2) and BxPC3, after 24 h of the indicated treatment. We labeled ERK1/2 as pERK1/2 when phosphorylated at Thr202/Tyr204. (D) Immunoblot analysis of the indicated proteins in MIA PaCa-2 (biallelic KRAS G12C ) and BxPC-3 (wild-type KRAS) cell lines treated as indicated for 24 h. Arrows indicate band shifts of KRAS molecules covalently bound by adagrasib or sotorasib. (E) Synergy plot in MIA PaCa-2 cells after 48 h in the presence of the indicated concentrations of sotorasib, LC-2, and BBCl. ATP levels were used as readouts of cell viability and metabolic activity. (F) Immunoblot analysis of the indicated proteins in MIA PaCa-2 ( KRAS G12C/G12C ), PANC-1 ( KRAS wt/G12D ), and SW620 ( KRAS G12V ) cells treated for 48 h with the indicated KRAS(OFF) and KRAS(ON) inhibitors. Arrows indicate band shifts of KRAS molecules covalently bound by RMC-9805. (G) Immunoblot analysis of the indicated proteins in PANC-1 cells treated for 48 h with the indicated μM concentrations of BBCl and/or RMC-9805. (H) Clonogenic assay in PANC-1 cells treated as indicated for 30 h and then grown in 35-mm plates for 7 days. (I) Clonogenic assay in PANC-1 RMCx3 cells treated as indicated for 30 h and then grown in 35-mm plates for 7 days. (J and K) Quantification of tumor volumes (J) and weight (K) in the BxPC-3 FLAG-KRAS G12C xenograft model. Nude mice were subcutaneously injected with 2 × 10 6 cells. When tumors reached a mean volume of ∼100 mm 3 , mice were randomized into four groups and treated intraperitoneally (i.p.) twice per week as indicated in  D. After the indicated number of days, mice were sacrificed, and tumors were excised (K). Data are expressed as mean ± st.error, n = 6. Statistical analysis was performed using one-way ANOVA followed by Bonferroni post hoc test.  (L) Immunoblot analysis of the indicated proteins and global peptidyl-citrullination levels in tumors excised from the indicated mice, corresponding to the numerical identifiers shown in K. Cleaved caspase-3 and covalent KRAS engagement by sotorasib are indicated. In (A, B, H, I, J, and K) data are presented as mean ± SD. In (A, B, H, I, and K), Dunn’s multiple comparison test was used. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.
Cleaved Parp1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cleaved+parp1/Cleaved+Caspase-3+(Asp175)+Antibody/pm41862889-99-14-16
Average 99 stars, based on 1 article reviews
cleaved parp1 - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

86
Epizyme Inc anti cleaved parp1 rabbit mab
PADI inhibition potentiates KRAS-targeted therapies and overcomes acquired resistance (A) ATP levels in MIA PaCa-2 cells treated as indicated for 36 h under normoxia or hypoxia (2% O 2 ). (B) Clonogenic assay in the indicated MIA PaCa-2 cells treated as indicated for 30 h and then grown in 60-mm plates for 7 days. Colonies were stained with methylene blue. (C) Immunoblot analysis of the indicated proteins in MIA PaCa-2 cells (parental or treated once or three times with LC-2) and BxPC3, after 24 h of the indicated treatment. We labeled ERK1/2 as pERK1/2 when phosphorylated at Thr202/Tyr204. (D) Immunoblot analysis of the indicated proteins in MIA PaCa-2 (biallelic KRAS G12C ) and BxPC-3 (wild-type KRAS) cell lines treated as indicated for 24 h. Arrows indicate band shifts of KRAS molecules covalently bound by adagrasib or sotorasib. (E) Synergy plot in MIA PaCa-2 cells after 48 h in the presence of the indicated concentrations of sotorasib, LC-2, and BBCl. ATP levels were used as readouts of cell viability and metabolic activity. (F) Immunoblot analysis of the indicated proteins in MIA PaCa-2 ( KRAS G12C/G12C ), PANC-1 ( KRAS wt/G12D ), and SW620 ( KRAS G12V ) cells treated for 48 h with the indicated KRAS(OFF) and KRAS(ON) inhibitors. Arrows indicate band shifts of KRAS molecules covalently bound by RMC-9805. (G) Immunoblot analysis of the indicated proteins in PANC-1 cells treated for 48 h with the indicated μM concentrations of BBCl and/or RMC-9805. (H) Clonogenic assay in PANC-1 cells treated as indicated for 30 h and then grown in 35-mm plates for 7 days. (I) Clonogenic assay in PANC-1 RMCx3 cells treated as indicated for 30 h and then grown in 35-mm plates for 7 days. (J and K) Quantification of tumor volumes (J) and weight (K) in the BxPC-3 FLAG-KRAS G12C xenograft model. Nude mice were subcutaneously injected with 2 × 10 6 cells. When tumors reached a mean volume of ∼100 mm 3 , mice were randomized into four groups and treated intraperitoneally (i.p.) twice per week as indicated in  D. After the indicated number of days, mice were sacrificed, and tumors were excised (K). Data are expressed as mean ± st.error, n = 6. Statistical analysis was performed using one-way ANOVA followed by Bonferroni post hoc test.  (L) Immunoblot analysis of the indicated proteins and global peptidyl-citrullination levels in tumors excised from the indicated mice, corresponding to the numerical identifiers shown in K. Cleaved caspase-3 and covalent KRAS engagement by sotorasib are indicated. In (A, B, H, I, J, and K) data are presented as mean ± SD. In (A, B, H, I, and K), Dunn’s multiple comparison test was used. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.
Anti Cleaved Parp1 Rabbit Mab, supplied by Epizyme Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cleaved+parp1/anti+cleaved+parp/pmc12972718-6-0-4
Average 86 stars, based on 1 article reviews
anti cleaved parp1 rabbit mab - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

95
Proteintech china a23483 cleaved parp1 mouse
PADI inhibition potentiates KRAS-targeted therapies and overcomes acquired resistance (A) ATP levels in MIA PaCa-2 cells treated as indicated for 36 h under normoxia or hypoxia (2% O 2 ). (B) Clonogenic assay in the indicated MIA PaCa-2 cells treated as indicated for 30 h and then grown in 60-mm plates for 7 days. Colonies were stained with methylene blue. (C) Immunoblot analysis of the indicated proteins in MIA PaCa-2 cells (parental or treated once or three times with LC-2) and BxPC3, after 24 h of the indicated treatment. We labeled ERK1/2 as pERK1/2 when phosphorylated at Thr202/Tyr204. (D) Immunoblot analysis of the indicated proteins in MIA PaCa-2 (biallelic KRAS G12C ) and BxPC-3 (wild-type KRAS) cell lines treated as indicated for 24 h. Arrows indicate band shifts of KRAS molecules covalently bound by adagrasib or sotorasib. (E) Synergy plot in MIA PaCa-2 cells after 48 h in the presence of the indicated concentrations of sotorasib, LC-2, and BBCl. ATP levels were used as readouts of cell viability and metabolic activity. (F) Immunoblot analysis of the indicated proteins in MIA PaCa-2 ( KRAS G12C/G12C ), PANC-1 ( KRAS wt/G12D ), and SW620 ( KRAS G12V ) cells treated for 48 h with the indicated KRAS(OFF) and KRAS(ON) inhibitors. Arrows indicate band shifts of KRAS molecules covalently bound by RMC-9805. (G) Immunoblot analysis of the indicated proteins in PANC-1 cells treated for 48 h with the indicated μM concentrations of BBCl and/or RMC-9805. (H) Clonogenic assay in PANC-1 cells treated as indicated for 30 h and then grown in 35-mm plates for 7 days. (I) Clonogenic assay in PANC-1 RMCx3 cells treated as indicated for 30 h and then grown in 35-mm plates for 7 days. (J and K) Quantification of tumor volumes (J) and weight (K) in the BxPC-3 FLAG-KRAS G12C xenograft model. Nude mice were subcutaneously injected with 2 × 10 6 cells. When tumors reached a mean volume of ∼100 mm 3 , mice were randomized into four groups and treated intraperitoneally (i.p.) twice per week as indicated in  D. After the indicated number of days, mice were sacrificed, and tumors were excised (K). Data are expressed as mean ± st.error, n = 6. Statistical analysis was performed using one-way ANOVA followed by Bonferroni post hoc test.  (L) Immunoblot analysis of the indicated proteins and global peptidyl-citrullination levels in tumors excised from the indicated mice, corresponding to the numerical identifiers shown in K. Cleaved caspase-3 and covalent KRAS engagement by sotorasib are indicated. In (A, B, H, I, J, and K) data are presented as mean ± SD. In (A, B, H, I, and K), Dunn’s multiple comparison test was used. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.
China A23483 Cleaved Parp1 Mouse, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cleaved+parp1/PARP1+Fusion+Protein/pm41713621-94-106-112
Average 95 stars, based on 1 article reviews
china a23483 cleaved parp1 mouse - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

Image Search Results


PADI inhibition potentiates KRAS-targeted therapies and overcomes acquired resistance (A) ATP levels in MIA PaCa-2 cells treated as indicated for 36 h under normoxia or hypoxia (2% O 2 ). (B) Clonogenic assay in the indicated MIA PaCa-2 cells treated as indicated for 30 h and then grown in 60-mm plates for 7 days. Colonies were stained with methylene blue. (C) Immunoblot analysis of the indicated proteins in MIA PaCa-2 cells (parental or treated once or three times with LC-2) and BxPC3, after 24 h of the indicated treatment. We labeled ERK1/2 as pERK1/2 when phosphorylated at Thr202/Tyr204. (D) Immunoblot analysis of the indicated proteins in MIA PaCa-2 (biallelic KRAS G12C ) and BxPC-3 (wild-type KRAS) cell lines treated as indicated for 24 h. Arrows indicate band shifts of KRAS molecules covalently bound by adagrasib or sotorasib. (E) Synergy plot in MIA PaCa-2 cells after 48 h in the presence of the indicated concentrations of sotorasib, LC-2, and BBCl. ATP levels were used as readouts of cell viability and metabolic activity. (F) Immunoblot analysis of the indicated proteins in MIA PaCa-2 ( KRAS G12C/G12C ), PANC-1 ( KRAS wt/G12D ), and SW620 ( KRAS G12V ) cells treated for 48 h with the indicated KRAS(OFF) and KRAS(ON) inhibitors. Arrows indicate band shifts of KRAS molecules covalently bound by RMC-9805. (G) Immunoblot analysis of the indicated proteins in PANC-1 cells treated for 48 h with the indicated μM concentrations of BBCl and/or RMC-9805. (H) Clonogenic assay in PANC-1 cells treated as indicated for 30 h and then grown in 35-mm plates for 7 days. (I) Clonogenic assay in PANC-1 RMCx3 cells treated as indicated for 30 h and then grown in 35-mm plates for 7 days. (J and K) Quantification of tumor volumes (J) and weight (K) in the BxPC-3 FLAG-KRAS G12C xenograft model. Nude mice were subcutaneously injected with 2 × 10 6 cells. When tumors reached a mean volume of ∼100 mm 3 , mice were randomized into four groups and treated intraperitoneally (i.p.) twice per week as indicated in  D. After the indicated number of days, mice were sacrificed, and tumors were excised (K). Data are expressed as mean ± st.error, n = 6. Statistical analysis was performed using one-way ANOVA followed by Bonferroni post hoc test.  (L) Immunoblot analysis of the indicated proteins and global peptidyl-citrullination levels in tumors excised from the indicated mice, corresponding to the numerical identifiers shown in K. Cleaved caspase-3 and covalent KRAS engagement by sotorasib are indicated. In (A, B, H, I, J, and K) data are presented as mean ± SD. In (A, B, H, I, and K), Dunn’s multiple comparison test was used. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.

Journal: Cell Reports

Article Title: PADI-dependent mitochondrial adaptation drives resistance to KRAS inhibitors

doi: 10.1016/j.celrep.2026.118016

Figure Lengend Snippet: PADI inhibition potentiates KRAS-targeted therapies and overcomes acquired resistance (A) ATP levels in MIA PaCa-2 cells treated as indicated for 36 h under normoxia or hypoxia (2% O 2 ). (B) Clonogenic assay in the indicated MIA PaCa-2 cells treated as indicated for 30 h and then grown in 60-mm plates for 7 days. Colonies were stained with methylene blue. (C) Immunoblot analysis of the indicated proteins in MIA PaCa-2 cells (parental or treated once or three times with LC-2) and BxPC3, after 24 h of the indicated treatment. We labeled ERK1/2 as pERK1/2 when phosphorylated at Thr202/Tyr204. (D) Immunoblot analysis of the indicated proteins in MIA PaCa-2 (biallelic KRAS G12C ) and BxPC-3 (wild-type KRAS) cell lines treated as indicated for 24 h. Arrows indicate band shifts of KRAS molecules covalently bound by adagrasib or sotorasib. (E) Synergy plot in MIA PaCa-2 cells after 48 h in the presence of the indicated concentrations of sotorasib, LC-2, and BBCl. ATP levels were used as readouts of cell viability and metabolic activity. (F) Immunoblot analysis of the indicated proteins in MIA PaCa-2 ( KRAS G12C/G12C ), PANC-1 ( KRAS wt/G12D ), and SW620 ( KRAS G12V ) cells treated for 48 h with the indicated KRAS(OFF) and KRAS(ON) inhibitors. Arrows indicate band shifts of KRAS molecules covalently bound by RMC-9805. (G) Immunoblot analysis of the indicated proteins in PANC-1 cells treated for 48 h with the indicated μM concentrations of BBCl and/or RMC-9805. (H) Clonogenic assay in PANC-1 cells treated as indicated for 30 h and then grown in 35-mm plates for 7 days. (I) Clonogenic assay in PANC-1 RMCx3 cells treated as indicated for 30 h and then grown in 35-mm plates for 7 days. (J and K) Quantification of tumor volumes (J) and weight (K) in the BxPC-3 FLAG-KRAS G12C xenograft model. Nude mice were subcutaneously injected with 2 × 10 6 cells. When tumors reached a mean volume of ∼100 mm 3 , mice were randomized into four groups and treated intraperitoneally (i.p.) twice per week as indicated in D. After the indicated number of days, mice were sacrificed, and tumors were excised (K). Data are expressed as mean ± st.error, n = 6. Statistical analysis was performed using one-way ANOVA followed by Bonferroni post hoc test. (L) Immunoblot analysis of the indicated proteins and global peptidyl-citrullination levels in tumors excised from the indicated mice, corresponding to the numerical identifiers shown in K. Cleaved caspase-3 and covalent KRAS engagement by sotorasib are indicated. In (A, B, H, I, J, and K) data are presented as mean ± SD. In (A, B, H, I, and K), Dunn’s multiple comparison test was used. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.

Article Snippet: Cleaved PARP1 , Proteintech , RRID: AB_331426.

Techniques: Inhibition, Clonogenic Assay, Staining, Western Blot, Analysis, Labeling, Activity Assay, Xenograft Assay, Injection, Comparison

PADI3 inhibition recapitulates the synergistic effects of BBCl in combination with KRAS inhibitors (A) Chemical structures of the three PADI inhibitors used in this study and their bibliographic reference. (B) PADI3 auto-citrullination assay performed in the presence of 10 μM of the indicated PADI inhibitors. (C) In vitro citrullination assay using 4MEBz-FluMe as a probe for citrullination activity and either a cocktail of PADIs (PADI1, 2, 3, 4, 6; left) or recombinant PADI3 (right) in the presence of increasing concentrations of PADI inhibitors. IC 50 values were determined by non-linear regression analysis using a variable-slope model. (D) Growth inhibition 50 (GI 50 ) of the indicated PADI inhibitors in MIA PaCa-2 V5 or PADI3-V5 cells treated for 72 h. GI 50 values were determined by non-linear regression analysis using a variable-slope model. (E and F) ATP levels in the indicated PDAC cells treated for 36 h with the indicated inhibitors. (G) Clonogenic assay in MIA PaCa-2 cells treated with LC-2 (2.5 μM), BBCl (5 μM), and the PADI3 inhibitor (CAY10727 “Cay”, 5 μM). (H and I) Quantification of tumor volumes (H) and weight (I) in the FC1199-P3 xenograft model. Nude mice were subcutaneously injected with 2 × 10 6 cells. When tumors reached a mean volume of ∼100 mm 3 , mice were randomized into four groups and treated intraperitoneally (i.p.) twice per week with RMC-9805 (10 mg/kg) and/or HF-4 (5 mg/kg), as indicated. After the indicated number of days, mice were sacrificed, and tumors were excised (I). Data are expressed as mean ± st.error, n = 6. (J) Immunoblot analysis of the indicated proteins and global peptidyl-citrullination levels in tumors excised from the indicated mice, corresponding to the numerical identifiers shown in I. Cleaved caspase-3 is indicated. In B-I, data are presented as mean ± SD. Dunn’s multiple comparison test was used in B-G. One-way ANOVA followed by a Bonferroni post hoc test was used in (H and I). ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.

Journal: Cell Reports

Article Title: PADI-dependent mitochondrial adaptation drives resistance to KRAS inhibitors

doi: 10.1016/j.celrep.2026.118016

Figure Lengend Snippet: PADI3 inhibition recapitulates the synergistic effects of BBCl in combination with KRAS inhibitors (A) Chemical structures of the three PADI inhibitors used in this study and their bibliographic reference. (B) PADI3 auto-citrullination assay performed in the presence of 10 μM of the indicated PADI inhibitors. (C) In vitro citrullination assay using 4MEBz-FluMe as a probe for citrullination activity and either a cocktail of PADIs (PADI1, 2, 3, 4, 6; left) or recombinant PADI3 (right) in the presence of increasing concentrations of PADI inhibitors. IC 50 values were determined by non-linear regression analysis using a variable-slope model. (D) Growth inhibition 50 (GI 50 ) of the indicated PADI inhibitors in MIA PaCa-2 V5 or PADI3-V5 cells treated for 72 h. GI 50 values were determined by non-linear regression analysis using a variable-slope model. (E and F) ATP levels in the indicated PDAC cells treated for 36 h with the indicated inhibitors. (G) Clonogenic assay in MIA PaCa-2 cells treated with LC-2 (2.5 μM), BBCl (5 μM), and the PADI3 inhibitor (CAY10727 “Cay”, 5 μM). (H and I) Quantification of tumor volumes (H) and weight (I) in the FC1199-P3 xenograft model. Nude mice were subcutaneously injected with 2 × 10 6 cells. When tumors reached a mean volume of ∼100 mm 3 , mice were randomized into four groups and treated intraperitoneally (i.p.) twice per week with RMC-9805 (10 mg/kg) and/or HF-4 (5 mg/kg), as indicated. After the indicated number of days, mice were sacrificed, and tumors were excised (I). Data are expressed as mean ± st.error, n = 6. (J) Immunoblot analysis of the indicated proteins and global peptidyl-citrullination levels in tumors excised from the indicated mice, corresponding to the numerical identifiers shown in I. Cleaved caspase-3 is indicated. In B-I, data are presented as mean ± SD. Dunn’s multiple comparison test was used in B-G. One-way ANOVA followed by a Bonferroni post hoc test was used in (H and I). ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.

Article Snippet: Cleaved PARP1 , Proteintech , RRID: AB_331426.

Techniques: Inhibition, In Vitro, Activity Assay, Recombinant, Analysis, Clonogenic Assay, Xenograft Assay, Injection, Western Blot, Comparison, Cell Viability Assay

Combined KRAS and PADI inhibition engages mitochondrial apoptosis while preserving plasma membrane integrity (A) MIA PaCa-2 cells were transduced with the Brunello CRISPR library targeting coding genes with 76,441 barcoded sgRNAs. After puromycin selection, cells were treated for 48 h with DMSO, LC-2+BBCl, adagrasib+BBCl, or sotorasib+BBCl. Resistant clones were then expanded for 120 h, genomic DNA was extracted, libraries were prepared, and barcodes were quantified and analyzed for abundance relative to the untreated (DMSO) condition. Enriched sgRNAs correlate with resistance and therefore target genes that regulate sensitivity to the proposed treatments. (B) Volcano plot of sgRNAs enriched or depleted across the four conditions tested (LC-2+BBCl, adagrasib+BBCl, sotorasib+BBCl vs. untreated). (C) Pathway analysis with Enrichr of sgRNAs enriched or depleted in the four conditions tested (LC-2+BBCl, adagrasib+BBCl, sotorasib+BBCl vs. untreated). For each functional category, p value and combined enrichment score are reported. (D) Positive or negative enrichment expressed as the mean fold change of sgRNAs targeting genes belonging to functional categories associated with anti-apoptotic, apoptotic, and ferroptotic responses. (E–G) Immunoblot of the indicated proteins in MIA PaCa-2 cells expressing Control (Hygro) or BCL-xL as indicated and treated with STS (1 μM, 24 h) or LC-2+BBCl (2.5 and 5 μM, respectively) for 72 h. Caspase processing (cleavage) is shown. For the detection of CASP3 and PARP1 cleavage, specific antibodies were used as indicated. (F) Bar graphs show ATP levels, extracellular LDH release, and caspase activity in MIA PaCa-2 cells expressing control (hygromycin resistance) or BCL-xL, as indicated, and treated for 48 h with STS (1 μM), LC-2+BBCl (2.5 and 5 μM), or LC-2+BBCl combined with Liproxstatin-1 (Lipro, 5 μM), ABT263 (1 μM), or MLKLi (5 μM). (H) Bar graph shows the percentage of MIA PaCa-2 cells expressing Control (Hygromycin resistance) or BCL-xL that become fluorescent in the presence of a probe monitoring Caspase-3 processing during 40 h of time-lapse microscopy under the indicated treatments. BBCl and HF4 were used at 5 μM. (I) Clonogenic assay in the indicated cells treated as described for 48 h and then allowed to grow for 10 days in 60-mm dishes. Colonies were stained with methylene blue at the end of the experiment. (J) Representative time-lapse images of MIA PaCa-2 cells expressing H2B-GFP (in green) and nls-mCherry (in magenta); for each image, the time in minutes of each frame from the start of the indicated treatment is shown (LC-2 2.5 μM, BBCl 5 μM, STS 1 μM). The arrows indicate: a. an event characterized by DNA fragmentation, release of nls-mCherry into the cytoplasm, preservation of overall nuclear structure, and maintenance of plasma membrane integrity; b. an event characterized by DNA fragmentation, cytoplasmic release of nls-mCherry, dismantling of nuclear structure, and maintenance of plasma membrane integrity; c. an event characterized by DNA fragmentation, cytoplasmic release of nls-mCherry, dismantling of nuclear structure, formation of apoptotic bodies, and subsequent loss of plasma membrane integrity. Scale bars, 25 μm. (K) Dot plot shows the minute after which one of the four indicated events occurs (the frame marking the start of the event is considered) or the “non-event”, meaning an event not identified during 1200 min of video recording. In (F, H, I, and K), data are shown as mean ± st.dev.; n = 3. Pairwise t test. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.

Journal: Cell Reports

Article Title: PADI-dependent mitochondrial adaptation drives resistance to KRAS inhibitors

doi: 10.1016/j.celrep.2026.118016

Figure Lengend Snippet: Combined KRAS and PADI inhibition engages mitochondrial apoptosis while preserving plasma membrane integrity (A) MIA PaCa-2 cells were transduced with the Brunello CRISPR library targeting coding genes with 76,441 barcoded sgRNAs. After puromycin selection, cells were treated for 48 h with DMSO, LC-2+BBCl, adagrasib+BBCl, or sotorasib+BBCl. Resistant clones were then expanded for 120 h, genomic DNA was extracted, libraries were prepared, and barcodes were quantified and analyzed for abundance relative to the untreated (DMSO) condition. Enriched sgRNAs correlate with resistance and therefore target genes that regulate sensitivity to the proposed treatments. (B) Volcano plot of sgRNAs enriched or depleted across the four conditions tested (LC-2+BBCl, adagrasib+BBCl, sotorasib+BBCl vs. untreated). (C) Pathway analysis with Enrichr of sgRNAs enriched or depleted in the four conditions tested (LC-2+BBCl, adagrasib+BBCl, sotorasib+BBCl vs. untreated). For each functional category, p value and combined enrichment score are reported. (D) Positive or negative enrichment expressed as the mean fold change of sgRNAs targeting genes belonging to functional categories associated with anti-apoptotic, apoptotic, and ferroptotic responses. (E–G) Immunoblot of the indicated proteins in MIA PaCa-2 cells expressing Control (Hygro) or BCL-xL as indicated and treated with STS (1 μM, 24 h) or LC-2+BBCl (2.5 and 5 μM, respectively) for 72 h. Caspase processing (cleavage) is shown. For the detection of CASP3 and PARP1 cleavage, specific antibodies were used as indicated. (F) Bar graphs show ATP levels, extracellular LDH release, and caspase activity in MIA PaCa-2 cells expressing control (hygromycin resistance) or BCL-xL, as indicated, and treated for 48 h with STS (1 μM), LC-2+BBCl (2.5 and 5 μM), or LC-2+BBCl combined with Liproxstatin-1 (Lipro, 5 μM), ABT263 (1 μM), or MLKLi (5 μM). (H) Bar graph shows the percentage of MIA PaCa-2 cells expressing Control (Hygromycin resistance) or BCL-xL that become fluorescent in the presence of a probe monitoring Caspase-3 processing during 40 h of time-lapse microscopy under the indicated treatments. BBCl and HF4 were used at 5 μM. (I) Clonogenic assay in the indicated cells treated as described for 48 h and then allowed to grow for 10 days in 60-mm dishes. Colonies were stained with methylene blue at the end of the experiment. (J) Representative time-lapse images of MIA PaCa-2 cells expressing H2B-GFP (in green) and nls-mCherry (in magenta); for each image, the time in minutes of each frame from the start of the indicated treatment is shown (LC-2 2.5 μM, BBCl 5 μM, STS 1 μM). The arrows indicate: a. an event characterized by DNA fragmentation, release of nls-mCherry into the cytoplasm, preservation of overall nuclear structure, and maintenance of plasma membrane integrity; b. an event characterized by DNA fragmentation, cytoplasmic release of nls-mCherry, dismantling of nuclear structure, and maintenance of plasma membrane integrity; c. an event characterized by DNA fragmentation, cytoplasmic release of nls-mCherry, dismantling of nuclear structure, formation of apoptotic bodies, and subsequent loss of plasma membrane integrity. Scale bars, 25 μm. (K) Dot plot shows the minute after which one of the four indicated events occurs (the frame marking the start of the event is considered) or the “non-event”, meaning an event not identified during 1200 min of video recording. In (F, H, I, and K), data are shown as mean ± st.dev.; n = 3. Pairwise t test. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.

Article Snippet: Cleaved PARP1 , Proteintech , RRID: AB_331426.

Techniques: Inhibition, Preserving, Clinical Proteomics, Membrane, Transduction, CRISPR, Selection, Clone Assay, Sensitivity, Analysis, Functional Assay, Western Blot, Expressing, Control, Activity Assay, Time-lapse Microscopy, Clonogenic Assay, Staining, Significance Assay, Cell Viability Assay, Caspase Activity Assay, Colony Assay, Live Cell Imaging

Journal: Cell Reports

Article Title: PADI-dependent mitochondrial adaptation drives resistance to KRAS inhibitors

doi: 10.1016/j.celrep.2026.118016

Figure Lengend Snippet:

Article Snippet: Cleaved PARP1 , Proteintech , RRID: AB_331426.

Techniques: